Folketrygdfondet Buys New Stake in Oculis Holding AG $OCS

Folketrygdfondet bought a new stake in Oculis Holding AG (NASDAQ:OCS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 182,800 shares of the company’s stock, valued at approximately $3,651,000. Oculis makes up approximately 0.2% of Folketrygdfondet’s holdings, making the stock its 10th biggest position. Folketrygdfondet owned approximately 0.35% of Oculis as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OCS. Geode Capital Management LLC lifted its stake in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after buying an additional 6,384 shares in the last quarter. Marshall Wace LLP purchased a new stake in Oculis in the 2nd quarter valued at approximately $393,000. Bank of America Corp DE lifted its stake in shares of Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the period. Woodline Partners LP lifted its stake in shares of Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares during the period. Finally, Aventura Private Wealth LLC purchased a new position in shares of Oculis during the 4th quarter worth $80,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Trading Up 0.3%

Shares of OCS opened at $11.00 on Friday. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $637.78 million, a P/E ratio of -5.16 and a beta of 0.23. The stock’s fifty day simple moving average is $25.30 and its 200 day simple moving average is $24.74. Oculis Holding AG has a twelve month low of $10.52 and a twelve month high of $34.47.

Oculis (NASDAQ:OCS) last issued its earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. On average, equities research analysts forecast that Oculis Holding AG will post -2.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Needham & Company LLC reduced their price target on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. JPMorgan Chase & Co. reduced their price target on Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating on shares of Oculis in a research note on Thursday. Finally, Robert W. Baird reduced their price target on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a research note on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.33.

Oculis Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.